#Japan #Tokyo #BioPhenoMA #TN-cyclon #ELISA Kit

BioPhenoMA's TN-cyclon™ ELISA Kit Featured in Funakoshi News

BioPhenoMA, a pioneering startup based in Shinjuku, Tokyo, has been making waves in the research community with its high-sensitivity protein quantification technology known as the TN-cyclon™ ELISA kit. This groundbreaking innovation was prominently featured in the August 2025 issue of Funakoshi News, a publication by Funakoshi Co., Ltd. The article, found on page 7, highlights the kit's contributions to precise quantification of trace proteins, particularly vital to cancer and immune research.

Publication Details

• - Magazine: Funakoshi News August 2025
• - Publication Date: August 1, 2025
• - Publisher: Funakoshi Co., Ltd.
• - Page: 7
• - PDF Access: Download PDF
• - Official Site: Funakoshi Co., Ltd.

Product Overview

The TN-cyclon™ ELISA kit debuted with two main products aimed at researchers:

• - PD-L1 TN-cyclon™ ELISA kit (for research use)
• - TN-cyclon™ ELISA Development Kit (for research use)

These products leverage BioPhenoMA's proprietary TN-cyclon™ technology, which opens up new avenues for detecting ultra-low levels of proteins that were challenging to measure using traditional ELISA methods. As a result, it significantly enhances data analysis accuracy in research areas related to cancer and autoimmune diseases.

Commitment to Research

BioPhenoMA is committed to providing comprehensive support for research needs. With two research reagents currently in their lineup, they also offer a protein measurement service that employs their innovative technology. This one-stop solution aims to meet the increasing demand for high-sensitivity quantification in research.

About BioPhenoMA

Founded on April 18, 2023, BioPhenoMA was established to transform the landscape of biomedical research. The company builds upon the expertise of Professor Etsuro Ito from Waseda University, who played a significant role in developing the revolutionary TN-cyclon™ technology. This technique enables the ultra-sensitive measurement of trace proteins present in biological fluids like blood and exosomes using standard ELISA methods.

The mission of BioPhenoMA is straightforward yet ambitious: to create an innovative platform that empowers researchers with the capability to conduct trace protein detection easily, irrespective of location. The company aims to foster advancements in the biomedical field, contributing to a deeper understanding of biological phenomena.

Contact Information

Company Name: BioPhenoMA
Establishment: April 18, 2023
Address: 1-22-3 Nishiwaseda, Shinjuku, Tokyo
CEO: Makoto Mitamura
Website: BioPhenoMA Official Site
Email: [email protected]

As BioPhenoMA continues to advance its offerings and support groundbreaking research with the TN-cyclon™ technology, the company's recognition in Funakoshi News cements its role as a critical player in the realm of high-sensitivity protein detection.